OOIR: Observatory of International Research

Papers

(The H4-Index of Multiple Sclerosis Journal is 30. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-05-01 to 2025-05-01.)

Article	Citations
An interdisciplinary approach is necessary in the treatment of cognitive decline in MS: No	83
Time to move past typical syndromes in the diagnosis of multiple sclerosis	61
Erratum to “Ofatumumab-induced severe reactivation of psoriasis in a patient with multiple sclerosis” Multiple Sclerosis Journal; 2024: 30(8); 1086–1088. DOI: 10.1177/13524585241260564.	60
Presymptomatic MS or radiologically isolated syndrome should be actively monitored and treated: Commentary	57
Natalizumab concentrations during pregnancy in three patients with multiple sclerosis: A clinical commentary	54
Cerebrospinal fluid–related tissue damage in multiple sclerosis patients with iron rim lesions	52
Reply to letter to the editor: Olfactory threshold as a biomarker of disease activity	51
Therapy challenges for NMOSD in a patient with HIV	51
Cortical ischemic lesions from atrial myxoma as a mimic of disease activity in an RRMS antiCD20-treated patient	50
All Bruton’s tyrosine kinase inhibitors have similar efficacy and risks: Yes	50
Safety of anti-varicella zoster virus vaccination in patients with multiple sclerosis treated with natalizumab: A case series	47
Therapy with mesenchymal stem cell transplantation in multiple sclerosis is ready for prime time: No	47
Sars-CoV2 infection in pregnant women with multiple sclerosis	45
Stable multiple sclerosis patients on anti-CD20 therapy should go on extended interval dosing: NO	41
ACTRIMS Forum 2021 – Invited Program	41
Productivity loss among people with early multiple sclerosis: A Canadian study	41
Autoimmune glomerulonephritis in a multiple sclerosis patient after cladribine treatment	40
Progression independent of relapse activity in multiple sclerosis: Time to account for cognitive decline	39
Immunoglobulin G immune response to SARS-CoV-2 vaccination in people living with multiple sclerosis within Multiple Sclerosis Partners Advancing Technology and Health Solutions	39
GM-CSF is a marker of compartmentalised intrathecal inflammation in multiple sclerosis	38
Humoral immune response after COVID-19 in multiple sclerosis: A nation-wide Austrian study	35
The MoXFo initiative – study design: Considerations related to study design and methodology in exercise research for people with multiple sclerosis	35
Decentralised clinical trials in multiple sclerosis research	35
Neurophysiological MEG markers of cognitive impairment and performance validity in multiple sclerosis	32
Extended interval dosing of ocrelizumab in patients with multiple sclerosis is not associated with meaningful differences in disease activity	32

Paramagnetic rim lesions predict greater long-term relapse rates and clinical progression over 10 years	31
Thematic analysis of multiple sclerosis research by enhanced strategic diagram	31
Rapid and sustained B-cell depletion with subcutaneous ofatumumab in relapsing multiple sclerosis: APLIOS, a randomized phase-2 study	31
Double-negative neuromyelitis optica spectrum disorder	30
The Response Study: A French registry on pregnancy in women with MS and related disorders and their children up to 6 years—Protocol, recruitment status, and baseline characteristics	30